The wnt pathway in mood disorders

Current Neuropharmacology

Volumn 10, Issue 3, 2012, Pages 239-253

  Sani, Gabriele ^a,b   Napoletano, Flavia ^a   Forte, Alberto Maria ^a,c   Kotzalidis, Giorgio D ^a   Panaccione, Isabella ^a,c   Porfiri, Giulio Maria ^a   Simonetti, Alessio ^a,b   Caloro, Matteo ^a   Girardi, Nicoletta ^a   Telesforo, Carla Ludovica ^a   Serra, Giulia ^a,b   Romano, Silvia ^a   Manfredi, Giovanni ^a   Savoja, Valeria ^a   Tamorri, Stefano Maria ^a   Koukopoulos, Alexia E ^a,b   Serata, Daniele ^a   Rapinesi, Chiara ^a,e   Casale, Antonio Del ^a   Nicoletti, Ferdinando ^c,d   Girardi, Paolo ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Centro Lucio Bini   (Italy)

^c IRCCS NEUROMED   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Department of Neuropsychiatry ^*  (Italy)

Author keywords

Antidepressant Drugs; Antipsychotic Drugs; Bipolar Disorder; Major Depression; Mood Disorders; Mood Stabilising Agents; Wingless (Wnt) signalling

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOZAPINE; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ARTICLE; AUTOPSY; BEHAVIOR; BIPOLAR DISORDER; DEPRESSION; DRUG MECHANISM; HEREDITY; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MEDLINE; MOOD DISORDER; NERVE CELL DIFFERENTIATION; NONHUMAN; PROTEIN PHOSPHORYLATION; SUICIDAL IDEATION; SUICIDE; WNT SIGNALING PATHWAY;

EID: 84867564968     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912803217279     Document Type: Article

References (183)

1. Peifer, M.; Rauskolb, C.; Williams, M.; Riggleman, B.; Wieschaus, E. The segment polarity gene armadillo interacts with the wingless signalling pathway in both embryonic and adult pattern formation. Development, 1991, 111, 1029-1043.
2. Ille, F.; Sommer, L. Wnt signalling: multiple functions in neural development. Cell. Mol. Life Sci., 2005, 62, 1100-1108.
3. Fišar, Z.; Hroudová, J. Intracellular signalling pathways and mood disorders. Folia Biol (Praha), 2010, 56, 135-148.
4. De Ferrari, G. V.; Moon, R. T. The ups and downs of Wnt signalling in prevalent neurological disorders. Oncogene, 2006, 25, 7545-7553.
5. Cotter, D.; Kerwin, R.; al-Sarraji, S.; Brion, JP.; Chadwich, A.; Lovestone, S.; Anderton, B.; Everall, I. Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental abnormality. Neuroreport, 1998, 9, 1379-1383.
6. Miyaoka, T.; Seno, H.; Ishino, H. Increased expression of Wnt-1 in schizophrenic brains. Schizophr. Res., 1999, 38, 1-6.
7. Klein, PS.; Melton, D. A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 8455-8459.
8. Hedgepeth, C. M.; Conrad, L. J.; Zhang, J.; Huang, H. C.; Lee, V. M.; Klein, P. S. Activation of the Wnt signalling pathway: a molecular mechanism for lithium action. Dev. Biol., 1997, 185, 82-91.
9. Detera-Wadleigh, S. D. Lithium-related genetics of bipolar disorder. Ann. Med., 2001, 33, 272-285.
10. Gould, T. D.; Manji, H. K. Signalling networks in the pathophysiology and treatment of mood disorders. J. Psychosom. Res., 2002, 53, 687-697.
11. Gould, T. D.; Dow, E. R.; O'Donnell, K. C.; Chen, G.; Manji, H. K. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol. Disord. Drug Targets, 2007, 6, 193-204.
12. Hu, L. W.; Kawamoto, E. M.; Brietzke, E.; Scavone, C.; Lafer, B. The role of Wnt signalling and its interaction with diverse mechanisms of cellular apoptosis in the pathophysiology of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35, 11-17.
13. Komiya, Y.; Habas, R. Wnt signal transduction pathways. Organogenesis, 2008, 4, 68-75.
14. Lie, D. C.; Colamarino, S. A.; Song, H. J.; Desire, L.; Mira, H.; Consiglio, A.; Lein, E. S.; Jessberger, S.; Lansford, H.; Dearie, A. R.; Gage, F. H. Wnt signalling regulates adult hippocampal neurogenesis. Nature, 2005, 437, 1370-1375.
15. Logan, C. W.; Nusse, R. The Wnt signalling pathway in development and disease. Cell. Dev. Biol., 2004, 20, 781-810.
16. Okerlund, N. D.; Cheyette, B. N. R. Synaptic Wnt signalling. A contributor to major psychiatric disorders? J. Neurodev. Disord., 2011, 3, 162-174.
17. Gao, C.; Chen, Y. G. Dishevelled: The hub of Wnt signalling. Cell. Signal., 2010, 22, 717-727.
18. Doble, B. W.; Woodgett, J. R. GSK-3: tricks of the trade for a multitasking kinase. J. Cell. Sci., 2003, 116, 1175-1186.
19. Gurvich, N.; Klein, P. S. Lithium and valproic acid: parallels and contrasts in diverse signalling contexts. Pharmacol. Ther., 2002, 96, 45-66.
20. McManus, E. J.; Sakamoto, K.; Armit, L. J.; Ronaldson, L.; Shpiro, N.; Marquez, R.; Alessi, D. R. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J., 2005, 24, 1571-1583.
21. Fukumoto, S.; Hsieh, C. M.; Maemura, K.; Layne, M. D.; Yet, S. F.; Lee, K. H.; Matsui, T.; Rosenzweig, A.; Taylor, W. G.; Rubin, J. S.; Perrella, M. A.; Lee, M. E. Akt participation in the Wnt signalling pathway through Dishevelled. J. Biol. Chem., 2001, 276, 17479-17483.
22. Sugimura, R.; Li, L. Noncanonical Wnt signalling in vertebrate development, stem cells, and diseases. Birth Defects Res. C Embryo Today, 2010, 90, 243-256.
23. Ishitani, T.; Ninomiya-Tsuji, J.; Nagai, S.; Nishita, M.; Meneghini, M.; Barker, N.; Waterman, M.; Bowerman, B.; Clevers, H.; Shibuya, H.; Matsumoto, K. The TAK1-NLK-MAPK-related pathway antagonizes signalling between β-catenin and transcription factor TCF. Nature, 1999, 399, 798-802.
24. 2+ pathway to antagonize Wnt/beta-catenin signalling. Mol. Cell. Biol., 2003, 23, 131-139.
25. Li, M.; Wang, H.; Huang, T.; Wang, J.; Ding, Y.; Li, Z.; Zhang, J.; Li, L. TAB2 scaffolds TAK1 and NLK in repressing canonical Wnt signalling. J. Biol. Chem., 2010, 285, 13397-13404.
26. Kohn, A. D.; Moon, R. T. Wnt and calcium signalling: β-Catenin-independent pathways. Cell Calcium, 2005, 38, 439-446.
27. Habas, R.; He, X. Activation of Rho and Rac by Wnt/frizzled signalling. Methods Enzymol., 2006, 406, 500-511.
28. Mlodzik, M. Planar cell polarisation: do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation? Trends Genet., 2002, 18, 564-571.
29. Simons, M.; Mlodzik, M. Planar cell polarity signalling: from fly development to human disease. Annu. Rev. Genet., 2008, 42, 517-540.
30. Stevens, H. E.; Smith, K. M.; Rash, B. G.; Vaccarino, F. M. Neural stem cell regulation, fibroblast growth factors, and the developmental origins of neuropsychiatric disorders. Front. Neurosci., 2010, 4, 59.
31. Thomas, K. R.; Capecchi, M. R. Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature, 1990, 346, 847-850.
32. Machon, O.; Backman, M.; Machonova, O.; Kozmik, Z.; Vacik, T.; Andersen, L.; Krauss, S. A dynamic gradient of Wnt signalling controls initiation of neurogenesis in the mammalian cortex and cellular specification in the hippocampus. Dev. Biol., 2007, 311, 223-237.
33. Patapoutian, A.; Reichardt, L. F. Roles of Wnt proteins in neural development and maintenance. Curr. Opin. Neurobiol., 2000, 10, 392-399.
34. Hur, E. M.; Zhou, F. Q. GSK3 signalling in neural development. Nat. Rev. Neurosci., 2010, 11, 539-551.
35. Cerpa, W.; Toledo, E. M.; Varela-Nallar, L.; Inestrosa, N. C. The role of Wnt signalling in neuroprotection. Drug News Perspect., 2009, 22, 579-591.
36. Harrison, P. J.; Weinberger, D. R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry, 2005, 10, 40-68. Errata corrige 10, 420; 10, 804.
37. Fatemi, S. H.; Folsom, T. D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull., 2009, 35, 528-548.
38. Guilmatre, A.; Dubourg, C.; Mosca, A. L.; Legallic, S.; Goldenberg, A.; Drouin-Garraud, V.; Layet, V.; Rosier, A.; Briault, S.; Bonnet-Brilhault, F.; Laumonnier, F.; Odent, S.; Le Vacon, G.; Joly-Helas, G.; David, V.; Bendavid, C.; Pinoit, J. M.; Henry, C.; Impallomeni, C.; Germano, E.; Tortorella, G.; Di Rosa, G.; Barthelemy, C.; Andres, C.; Faivre, L.; Frébourg, T.; Saugier Veber, P.; Campion, D. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch. Gen. Psychiatry, 2009, 66, 947-956.
39. Blumberg, H. P.; Kaufman, J.; Martin, A.; Charney, D. S.; Krystal, J. H.; Peterson, B. S. Significance of adolescent neurodevelopment for the neural circuitry of bipolar disorder. Ann. N. Y. Acad. Sci., 2004, 1021, 376-383.
40. Vaidya, C. J. Neurodevelopmental abnormalities in ADHD. Curr. Top. Behav. Neurosci., May 4. 2011, Epub ahead of print, doi:10. 1007/7854. 2011. 38.
41. Sutcliffe, J. S. Heterogeneity and the design of genetic studies in autism. Autism Res., 2008, 1, 205-206.
42. Bourgeron, T.; Leboyer, M.; Delorme, R. Autism: more evidence of a genetic cause. Bull. Acad. Natl. Med., 2009, 193, 299-305.
43. Lovestone, S.; Killick, R.; Di Forti, M.; Murray, R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci., 2007, 30, 142-149.
44. Scassellati, C.; Bonvicini, C.; Perez, J.; Bocchio-Chiavetto, L.; Tura, G. B.; Rossi, G.; Racagni, G.; Gennarelli, M. Association study of-1727 A/T, -50 C/T and (CAA)n repeat GSK-3beta gene polymorphisms with schizophrenia. Neuropsychobiology, 2004, 50, 16-20.
45. Kozlovsky, N.; Belmaker, R. H.; Agam, G. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur. Neuropsychopharmacol., 2002, 12, 13-25.
46. O'Brien, W. T.; Harper, A. D.; Jové, F.; Woodgett, J. R.; Maretto, S.; Piccolo, S.; Klein, P. S. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci., 2004, 24, 6791-6798.
47. Beaulieu, J. M.; Sotnikova, T. D.; Yao, W. D.; Kockeritz, L.; Woodgett, J. R.; Gainetdinov, R. R.; Caron, M. G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signalling cascade. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 5099-5104.
48. Spittaels, K.; Van den Haute, C.; Van Dorpe, J.; Terwel, D.; Vandezande, K.; Lasrado, R.; Bruynseels, K.; Irizarry, M.; Verhoye, M.; Van Lint, J.; Vandenheede, J. R.; Ashton, D.; Mercken, M.; Loos, R.; Hyman, B.; Van der Linden, A.; Geerts, H.; Van Leuven, F. Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice. Neuroscience, 2002, 113, 797-808.
49. Beaulieu, J. M.; Zhang, X.; Rodriguiz, R. M.; Sotnikova, T. D.; Cools, M. J.; Wetsel, W. C.; Gainetdinov, R. R.; Caron, M. G. Role of GSK3β in behavioral abnormalities induced by serotonin deficiency. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 1333-1338.
50. Bersudsky, Y.; Shaldubina, A.; Kozlovsky, N.; Woodgett, J. R.; Agam, G.; Belmaker, R. H. Glycogen synthase kinase-3β heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav. Pharmacol., 2008, 19, 217-224.
51. Prickaerts, J.; Moechars, D.; Cryns, K.; Lenaerts, I.; van Craenendonck, H.; Goris, I.; Daneels, G.; Bouwknecht, J. A.; Steckler, T. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J. Neurosci., 2006, 26, 9022-9029.
52. Ackermann TF.; Kempe DS.; Lang F.; Lang UE. Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase kinase-3 (GSK-3). Cell. Physiol. Biochem., 2010, 25, 775-786.
53. Wilkinson, M. B.; Dias, C.; Magida, J.; Mazei-Robison, M.; Lobo, M.; Kennedy, P.; Dietz, D.; Covington, H.; Russo, S.; Neve, R.; Ghose, S.; Tamminga, C.; Nestler, E. J. A novel role of the WNT-dishevelled-GSK3β signalling cascade in the mouse nucleus accumbens in a social defeat model of depression. J. Neurosci., 2011, 31, 9084-9092.
54. Kaidanovich-Beilin, O.; Lipina, T. V.; Takao, K.; van Eede, M.; Hattori, S.; Laliberté, C.; Khan, M.; Okamoto, K.; Chambers, J. W.; Fletcher, P. J.; MacAulay, K.; Doble, B. W.; Henkelman, M.; Miyakawa, T.; Roder, J.; Woodgett, J. R. Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol. Brain, 2009, 2, 35.
55. Polter, A.; Beurel, E.; Yang, S.; Garner, R.; Song, L.; Miller, C. A.; Sweatt, J. D.; McMahon, L.; Bartolucci, A. A.; Li, X.; Jope, R. S. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology, 2010, 35, 1761-1774.
56. Liang, M. H.; Chuang, D. M. Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J. Biol. Chem., 2006, 281, 30479-30484.
57. Liang, M. H.; Chuang, D. M. Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J. Biol. Chem., 2007, 282, 3904-3917.
58. Lucas, J. J.; Hernández, F.; Gómez-Ramos, P.; Morán, M. A.; Hen, R.; Avila, J. Decreased nuclear beta-catenin, tau hyper-phosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J., 2001, 20, 27-39.
59. Gould, T. D.; Einat, H.; Bhat, R.; Manji, H. K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol., 2004, 7, 387-390.
60. Kaidanovich-Beilin, O.; Milman, A.; Weizman, A.; Pick, C. G.; Eldar-Finkelman, H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry, 2004, 55, 781-784.
61. Rosa, A. O.; Kaster, M. P.; Binfaré, R. W.; Morales, S.; Martín-Aparicio, E.; Navarro-Rico, M. L.; Martinez, A.; Medina, M.; García, A. G.; López, M. G.; Rodrigues, A. L. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32, 1549-1556.
62. Kaladchibachi, S. A.; Doble, B.; Anthopoulos, N.; Woodgett, J. R.; Manoukian, A. S. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J. Circadian Rhythms, 2007, 5, 3.
63. Schloesser, R. J.; Huang, J.; Klein, P. S.; Manji, H. K. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology, 2008, 33, 110-133.
64. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR); American Psychiatric Publishing: Washington, D. C., 2000, pp. 345-428.
65. Gould, T. D.; Quiroz, J. A.; Singh, J.; Zarate, C. A.; Manji, H. K. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilisers. Mol. Psychiatry, 2004, 9, 734-755.
66. Chen, G.; Huang, L. D.; Jiang, Y. M.; Manji, H. K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem., 1999, 72, 1327-1330.
67. De Sarno, P.; Li, X.; Jope, R. S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology, 2002, 43, 1158-1164.
68. Kozlovsky, N.; Amar, S.; Belmaker, R. H.; Agam, G. Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int. J. Neuropsychopharmacol., 2006, 9, 337-342.
69. Li, X.; Rosborough, K. M.; Friedman, A. B.; Zhu, W.; Roth, K. A. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol., 2007, 10, 7-19.
70. Rowe, M. K.; Wiest C.; Chuang, D. M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci. Biobehav. Rev., 2007, 31, 920-931.
71. Gould, T. D.; Chen, G.; Manji, H. K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology, 2004, 29, 32-38.
72. Drevets, W. C.; Price, J. L.; Simpson, J. R. Jr.; Todd, R. D.; Reich, T.; Vannier, M.; Raichle, M. E. Subgenual prefrontal cortex abnormalities in mood disorders. Nature, 1997, 386, 824-827.
73. Ongür, D.; Drevets, W. C.; Price, J. L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 13290-13295.
74. Rajkowska, G.; Miguel-Hidalgo, J. J.; Wei, J.; Dilley, G.; Pittman, S. D.; Meltzer, H. Y.; Overholser, J. C.; Roth, B. L.; Stockmeier, C. A. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry, 1999, 45, 1085-1098.
75. Kozlovsky, N.; Belmaker, R. H.; Agam, G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry, 2000, 157, 831-833.
76. Lesort, M.; Greendorfer, A.; Stockmeier, C.; Johnson, G. V.; Jope, R. S. Glycogen synthase kinase-3β, β-catenin, and τ in postmortem bipolar brain. J. Neural Transm., 1999, 106, 1217-1222.
77. Li, X.; Friedman, A. B.; Roh, M. S.; Jope, R. S. Anesthesia and post-mortem interval profoundly influence the regulatory serinephosphorylation of glycogen synthase kinase-3 in mouse brain. J. Neurochem., 2005, 92, 701-704.
78. Li, X.; Friedman, A. B.; Zhu, W.; Wang, L.; Boswell, S.; May, R. S.; Davis, L. L.; Jope, R. S. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol. Psychiatry, 2007, 61, 216-222; Erratum, 61, 261.
79. Li, X.; Liu, M.; Cai, Z.; Wang, G.; Li X. Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord., 2010, 12, 741-752.
80. Saus, E.; Soria, V.; Escaramís, G.; Crespo, J. M.; Valero, J.; Gutiérrez-Zotes, A.; Martorell, L.; Vilella, E.; Menchón, J. M.; Estivill, X.; Gratacòs, M.; Urretavizcaya, M. A haplotype of glycogen synthase kinase 3β is associated with early onset of unipolar major depression. Genes Brain Behav., 2010, 9, 799-807.
81. Matigian, N.; Windus, L.; Smith, H.; Filippich, C.; Pantelis, C.; McGrath, J.; Mowry, B.; Hayward, N. Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. Mol. Psychiatry, 2007, 12, 815-825.
82. Benedetti, F.; Serretti, A.; Colombo, C.; Lorenzi, C.; Tubazio, V.; Smeraldi, E. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci. Lett., 2004, 368, 123-126.
83. Benedetti, F.; Bernasconi, A.; Lorenzi, C.; Pontiggia, A.; Serretti, A.; Colombo, C.; Smeraldi, E. A single nucleotide polymorphism in glycogen synthase kinase 3-β promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci. Lett., 2004, 355, 37-40.
84. Benedetti, F.; Serretti, A.; Pontiggia, A.; Bernasconi, A.; Lorenzi, C.; Colombo, C.; Smeraldi, E. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-β-50 T/C SNP. Neurosci. Lett., 2005, 376, 51-55.
85. Youn-Jung L.; Yong-Ku K. The impact of glycogen synthase kinase 3β gene on psychotic mania in bipolar disorder patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35, 1303-1308.
86. Zandi, P. P.; Belmonte, P. L.; Willour, V. L.; Goes, F. S.; Badner, J. A.; Simpson, S. G.; Gershon, E. S.; McMahon, F. J.; DePaulo J. R. Jr.; Potash, J. B.; Bipolar Disorder Phenome Group; National Institute of Mental Health Genetics Initiative Bipolar Disorder Consortium. Association study of Wnt signalling pathway genes in bipolar disorder. Arch. Gen. Psychiatry, 2008, 65, 785-793.
87. Lachman HM.; Pedrosa E.; Petruolo OA.; Cockerham M.; Papolos A.; Novak T.; Papolos DF.; Stopkova P. Increase in GSK3β gene copy number variation in bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2007, 144B, 259-265.
88. Luykx, J. J.; Boks, M. P.; Terwindt, A. P.; Bakker, S.; Kahn, R. S. The involvement of GSK3β in bipolar disorder: integrating evidence from multiple types of genetic studies. Eur. Neuropsychopharmacol., 2010, 20, 357-368.
89. Pandey, G. N.; Ren, X.; Rizavi, H. S.; Dwivedi, Y. Glycogen synthase kinase-3β in the platelets of patients with mood disorders: effect of treatment. J. Psychiatr. Res., 2010, 44, 143-148.
90. Hashimoto, R.; Suzuki, T.; Iwata, N.; Yamanouchi, Y.; Kitajima, T.; Kosuga, A.; Tatsumi, M.; Osaki, N.; Kamijima, K.; Kunugi, H. Association study of the frizzled-3 (FZD3) gene with schizophrenia and mood disorders. J. Neural Transm., 2005, 112, 303-307.
91. Okamoto, H.; Voleti, B.; Banasr, M.; Sarhan, M.; Duric, V.; Girgenti, M. J.; Dileone, R. J.; Newton, S. S.; Duman, R. S. Wnt2 expression and signalling is increased by different classes of antidepressant treatments. Biol. Psychiatry, 2010, 68, 521-527.
92. Voleti, B.; Tanis, K. Q.; Newton, S. S.; Duman, R. S. Analysis of target genes regulated by chronic electroconvulsive therapy reveals role for Fzd6 in depression. Biol. Psychiatry, 2012; 71, 51-58.
93. 2+/ Calmodulin-dependent protein kinase II. Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 10732-10737.
94. Sahores, M.; Gibb, A.; Salinas, P. C. Frizzled-5, a receptor for the synaptic organizer Wnt7a, regulates activity-mediated synaptogenesis. Development, 2010, 137, 2215-2225.
95. Schulte, G.; Bryja, V. The Frizzled family of unconventional Gprotein-coupled receptors. Trends Pharmacol. Sci., 2007, 28, 518-525.
96. Banasr, M.; Valentine, G. W.; Li, X. Y.; Gourley, S. L.; Taylor, J. R.; Duman, R. S. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol. Psychiatry, 2007, 62, 496-504.
97. Banasr, M.; Duman, R. S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol. Psychiatry, 2008, 64, 863-870.
98. Yu, X.; Malenka, R. C. β-catenin is critical for dendritic morphogenesis. Nat. Neurosci., 2003, 6, 1169-1177.
99. Li, X.; Zhu, W.; Roh, MS.; Friedman, A. B.; Rosborough, K.; Jope, R. S. In vivo regulation of glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. Neuropsychopharmacology, 2004, 29, 1426-1431.
100. Inkster, B.; Nichols, T. E.; Saemann, P. G.; Auer, D. P.; Holsboer, F.; Muglia, P.; Matthews, P. M. Pathway-based approaches to imaging genetics association studies: Wnt signalling, GSK3beta substrates and major depression. NeuroImage, 2010, 53, 908-917.
101. Inkster, B.; Nichols, T. E.; Saemann, P. G.; Auer, D. P.; Holsboer, F.; Muglia, P.; Matthews, P. M. Association of GSK3β polymorphisms with brain structural changes in major depressive disorder. Arch. Gen. Psychiatry, 2009, 66, 721-728.
102. Tsai, S. J.; Liou, Y. J.; Hong, C. J.; Yu, Y. W.; Chen, T. J. Glycogen synthase kinase-3β gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenom., J., 2008, 8, 384-390.
103. Karege, F.; Perroud, N.; Burkhardt, S.; Schwald, M.; Ballmann, E.; La Harpe, R.; Malafosse, A. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol. Psychiatry, 2007, 61, 240-245.
104. Oh, D. H.; Park, Y. C.; Kim, S. H. Increased glycogen synthase kinase-3β mRNA level in the hippocampus of patients with major depression: a study using the stanley neuropathology consortium integrative database. Psychiatry Investig., 2010, 7, 202-207.
105. Yooh, H. K.; Kim, Y. K. Association between glycogen synthase kinase-3β gene polymorphisms and major depression and suicidal behavior in a Korean population. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34, 331-334.
106. Willour, V. L.; Seifuddin, F.; Mahon, P. B.; Jancic, D.; Pirooznia, M.; Steele, J.; Schweizer, B.; Goes, F. S.; Mondimore, F. M.; Mackinnon, D. F; The Bipolar Genome Study (BiGS) Consortium.; Perlis, R. H.; Lee, P. H.; Huang, J.; Kelsoe, J. R.; Shilling, P. D.; Rietschel, M.; Nöthen, M.; Cichon, S.; Gurling, H.; Purcell, S.; Smoller, J. W.; Craddock, N.; Depaulo, J. R. Jr.; Schulze, T. G.; McMahon, F. J.; Zandi, P. P.; Potash, J. B. A genome-wide association study of attempted suicide. Mol. Psychiatry, 2011, doi:10. 1038/mp. 2011. 4.
107. Manji, H. K.; Bebchuk, J. M.; Moore, G. J.; Glitz, D.; Hasanat, K. A.; Chen, G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J. Clin. Psychiatry, 1999, 60 (Suppl 2), 27-39.
108. Beaulieu, J. M.; Caron, M. G. Looking at lithium: molecular moods and complex behaviour. Mol. Interv., 2008; 8, 230-241.
109. Quiroz, J. A.; Gould, T. D.; Manji, H. K. Molecular effects of lithium. Mol. Interv., 2004, 4, 259-272.
110. Nonaka, S, Chuang, D. M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport, 1998, 9, 2081-2084.
111. Nonaka, S.; Hough, CJ.; Chuang, D. M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 2642-2647.
112. Nonaka, S.; Katsube, N.; Chuang, D. M. Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J. Pharmacol. Exp. Ther., 1998, 286, 539-547.
113. Alvarez, G.; Muñoz-Montaño, J. R.; Satrústegui, J.; Avila, J.; Bogónez, E.; Díaz-Nido, J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett., 1999, 453, 260-264.
114. Alvarez, G.; Muñoz-Montaño, J. R.; Satrústegui, J.; Avila, J.; Bogónez, E.; Díaz-Nido, J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord., 2002, 4, 153-165.
115. Wei, H.; Leeds, P. R.; Qian, Y.; Wei, W.; Chen, R.; Chuang, D. β-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. Eur. J. Pharmacol., 2000, 392, 117-123.
116. Wei, H.; Qin, Z. H.; Senatorov, V. V.; Wei, W.; Wang, Y.; Qian, Y.; Chuang, D. M. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience, 2001, 106, 603-612.
117. Manji, H. K.; Moore, G. J.; Chen, G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry, 1999, 46, 929-940.
118. Chalecka-Franaszek, E.; Chuang, D. M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 8745-8750.
119. Beaulieu, J. M.; Marion, S.; Rodriguiz, R. M.; Medvedev, I. O.; Sotnikova, T. D.; Ghisi, V.; Wetsel, W. C.; Lefkowitz, R. J.; Gainetdinov, R. R.; Caron, M. G. A beta-arrestin 2 signalling complex mediates lithium action on behavior. Cell, 2008, 132, 125-136.
120. Zhang, F.; Phiel, C. J.; Spece, L.; Gurvich, N.; Klein, P. S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem., 2003, 278, 33067-33077.
121. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci., 2003, 24, 441-443.
122. Adli, M.; Hollinde, D. L.; Stamm, T.; Wiethoff, K.; Tsahuridu, M.; Kirchheiner, J.; Heinz, A.; Bauer, M. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta-50T/C single nucleotide polymorphism. Biol. Psychiatry, 2007, 62, 1295-1302.
123. Szczepankiewicz, A.; Rybakowski, J. K.; Suwalska, A.; Skibinska, M.; Leszczynska-Rodziewicz, A.; Dmitrzak-Weglarz, M.; Czerski, P. M.; Hauser, J. Association study of the glycogen synthase kinase-3β gene polymorphism with prophylactic lithium response in bipolar patients. World J. Biol. Psychiatry, 2006, 7, 158-161.
124. Kozikowski, A. P.; Gunosewoyo, H.; Guo, S.; Gaisina, I. N.; Walter, R. L.; Ketcherside, A.; McClung, C. A.; Mesecar, A. D.; Caldarone, B. Identification of a Glycogen Synthase Kinase-3β Inhibitor that Attenuates Hyperactivity in CLOCK Mutant Mice. Chem. Med. Chem., 2011, 6, 1593-1602.
125. Roybal, K.; Theobold, D.; Graham, A.; DiNieri, J. A.; Russo, S. J.; Krishnan, V.; Chakravarty, S.; Peevey, J.; Oehrlein, N.; Birnbaum, S.; Vitaterna, M. H.; Orsulak, P.; Takahashi, J. S.; Nestler, E. J.; Carlezon, W. A. Jr.; McClung, C. A. Mania-like behavior induced by disruption of CLOCK. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 6406-6411.
126. Serretti, A.; Benedetti, F.; Mandelli, L.; Lorenzi, C.; Pirovano, A.; Colombo, C.; Smeraldi, E. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2003, 121, 35-38.
127. Benedetti, F.; Serretti, A.; Colombo, C.; Barbini, B.; Lorenzi, C.; Campori, E.; Smeraldi, E. Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2003, 123, 23-26.
128. Kishi, T.; Kitajima, T.; Ikeda, M.; Yamanouchi, Y.; Kinoshita, Y.; Kawashima, K.; Okochi, T.; Okumura, T.; Tsunoka, T.; Inada, T.; Ozaki, N.; Iwata, N. Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur. Arch. Psychiatry Clin. Neurosci., 2009, 259, 293-297.
129. Lee, K. Y, Song, J. Y.; Kim, S. H.; Kim, S. C.; Joo, E. J.; Ahn, Y. M.; Kim, Y. S. Association between CLOCK 3111T/C and preferred circadian phase in Korean patients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34, 1196-1201.
130. Bailer, U, Wiesegger, G, Leisch, F, Fuchs, K, Leitner, I, Letmaier, M, Konstantinidis, A, Stastny, J, Sieghart, W, Hornik, K, Mitterauer, B, Kasper, S, Aschauer, H. N. No association of clock gene T3111C polymorphism and affective disorders. Eur. Neuropsychopharmacol., 2005, 15, 51-55.
131. Kishi, T.; Yoshimura, R.; Fukuo, Y.; Kitajima, T.; Okochi, T.; Matsunaga, S.; Inada, T.; Kunugi, H.; Kato, T.; Yoshikawa, T.; Ujike, H.; Umene-Nakano, W.; Nakamura, J.; Ozaki, N.; Serretti, A.; Correll, C. U.; Iwata, N. The CLOCK gene and mood disorders: a case-control study and meta-analysis. Chronobiol. Int., 2011, 28, 825-833.
132. Kalinichev, M.; Dawson, L. A. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int. J. Neuropsychopharmacol., 2011, 14, 1051-1067.
133. Vasconcellos, A. P.; Tabajara, A. S.; Ferrari, C.; Rocha, E.; Dalmaz, C. Effect of chronic stress on spatial memory in rats is attenuated by lithium treatment. Physiol. Behav., 2003, 79, 143-149.
134. Wood, G. E.; Young, L. T.; Reagan, L. P.; Chen, B.; McEwen, B. S. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 3973-3978.
135. Silva, R.; Mesquita, A. R.; Bessa, J.; Sousa, J. C.; Sotiropoulos, I.; Leão, P.; Almeida, O. F.; Sousa, N. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3β. Neuroscience, 2008, 152, 656-669.
136. Fountoulakis, K. N.; Vieta, E.; Sanchez-Moreno, J.; Kaprinis, S. G.; Goikolea, J. M.; Kaprinis, G. S. Treatment guidelines for bipolar disorder: a critical review. J. Affect. Disord., 2005, 86, 1-10.
137. Bowden, C. L. Valproate. Bipolar Disord., 2003, 5, 189-202.
138. Werstuck, G. H.; Kim, A. J.; Brenstrum, T.; Ohnmacht, S. A.; Panna, E.; Capretta, A. Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds. Bioorg. Med. Chem. Lett., 2004, 14, 5465-5467.
139. Kim, A. J.; Shi, Y.; Austin, R. C.; Werstuck, G. H. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci., 2005, 118, 89-99.
140. Phiel, C. J.; Zhang, F.; Huang, E. Y.; Guenther, M. G.; Lazar, M. A.; Klein, P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabiliser, and teratogen. J. Biol. Chem., 2001, 276, 36734-36741.
141. Hall, A. C.; Brennan, A.; Goold, R. G.; Cleverley, K.; Lucas, F. R.; Gordon-Weeks, P. R.; Salinas, P. C. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell Neurosci., 2002, 20, 257-270.
142. Eickholt, B. J.; Towers, G. J.; Ryves, W. J.; Eikel, D.; Adley, K.; Ylinen, L. M.; Chadborn, N. H.; Harwood, A. J.; Nau, H.; Williams, R. S. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. Mol. Pharmacol., 2005, 67, 1426-1433.
143. Jin, N.; Kovacs, A. D.; Sui, Z.; Dewhurst, S.; Maggirwar, S. B. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology, 2005, 48, 576-583.
144. Grimes, C. A.; Jope, R. S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J. Neurochem., 2001, 78, 1219-1232.
145. Leng, Y.; Liang, M. H.; Ren, M.; Marinova, Z.; Leeds, P.; Chuang, D. M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci., 2008, 28, 2576-2588.
146. Lamarre, M.; Desrosiers, RR. Up-regulation of protein l-isoaspartyl methyltransferase expression by lithium is mediated by glycogen synthase kinase-3 inactivation and beta-catenin stabilisation. Neuropharmacology, 2008, 55, 669-676.
147. Aubry, J. M.; Schwald, M.; Ballmann, E.; Karege, F. Early effects of mood stabilisers on the Akt/ GSK-3beta signalling pathway and on cell survival and proliferation. Psychopharmacology (Berl), 2009, 205, 419-429.
148. Ryves, W. J.; Dalton, E. C.; Harwood, A. J.; Williams, R. S. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord., 2005, 7, 260-265.
149. Tong, N.; Sanchez, J. F.; Maggirwar, S. B.; Ramirez, S. H.; Guo, H.; Dewhurst, S.; Gelbard, H. A. Activation of glycogen synthase kinase 3 beta (GSK-3β) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur. J. Neurosci., 2001, 13, 1913-1922.
150. Kozlovsky, N.; Nadri, C.; Belmaker, R. H.; Agam, G. Lack of effect of mood stabilisers or neuroleptics on GSK-3 protein levels and GSK-3 activity. Int. J. Neuropsychopharmacol., 2003, 6, 117-120.
151. Roh, M. S.; Eom, T. Y.; Zmijewska, A. A.; De Sarno, P.; Roth, K. A.; Jope, R. S. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilisers and imipramine. Biol. Psychiatry, 2005, 57, 278-286.
152. Zhou, R.; Yuan, P.; Wang, Y.; Hunsberger, J. G.; Elkahloun, A.; Wei, Y.; Damschroder-Williams, P.; Du, J.; Chen, G.; Manji, H. K. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilisers. Neuropsychopharmacology, 2009, 34, 1395-1405.
153. Agam, G.; Shaltiel, G.; Kozlovsky, N.; Shimon, H.; Belmaker, R. H. Lithium inhibitable enzymes in postmortem brain of bipolar patients. J. Psychiatr. Res., 2003, 37, 433-442.
154. Beasley, C.; Cotter, D.; Everall, I. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr. Res., 2002, 58, 63-67.
155. Mai, L.; Jope, R. S.; Li, X. BPNF-mediated signal transduction is modulated by GSK3β and mood stabilizing agents. J. Neurochem., 2002, 82, 75-83.
156. Weinberger, D. R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry, 1987, 44, 660-669.
157. Weinberger, D. R.; Berman, K. F.; Illowsky, B. P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry, 1988, 45, 609-615.
158. Breier, A.; Su, T. P.; Saunders, R.; Carson, R. E.; Kolachana, B. S.; de Bartolomeis, A.; Weinberger DR.; Weisenfeld, N.; Malhotra, A. K.; Eckelman, W. C.; Pickar, D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 2569-2574.
159. Molina, V.; Sanz, J.; Sarramea, F.; Benito, C.; Palomo, T. Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity. J. Psychiatr. Res., 2005, 39, 117-127.
160. Beaulieu, J. M.; Gainetdinov, R. R.; Caron, MG. The Akt-GSK-3 signalling cascade in the actions of dopamine. Trends Pharmacol. Sci., 2007, 28, 166-172.
161. Kang, U. G.; Seo, M, S.; Roh, M. S.; Kim, Y.; Yoon, S. C.; Kim, Y. S. The effects of clozapine on the GSK-3-mediated signalling pathway. FEBS Lett., 2004, 560, 115-119.
162. Sutton, L. P.; Honardoust, D.; Mouyal, J.; Rajakumar, N.; Rushlow, W. J. Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves disheveled-3. J. Neurochem., 2007, 102, 153-169.
163. Beaulieu, J. M. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int. J. Neuropsychopharmacol., 2007, 10, 3-6.
164. Beaulieu, J. M.; Gainetdinov, R. R.; Caron, M. G. Akt/GSK3 signalling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol., 2009, 49, 327-347.
165. Sutton, L. P.; Rushlow, W. J. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signalling. Neuroscience, 2011, 199, 116-24.
166. Alimohamad, H.; Rajakumar, N.; Seah, Y. H.; Rushlow, W. Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiatry, 2005, 57, 533-542.
167. Alimohamad, H.; Sutton, L.; Mouyal, J.; Rajakumar, N.; Rushlow, W. J. The effects of antipsychotics on β-catenin, glycogen synthase kinase-3 and disheveled in the ventral midbrain of rats. J. Neurochem., 2005, 95, 513-525.
168. Roh, M. S.; Seo, M. S.; Kim, Y.; Kim, S. H.; Jeon, W. J.; Ahn, Y. M.; Kang, U. G.; Juhnn, Y. S.; Kim, Y. S. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp., Mol., Med., 2007, 39, 353-360.
169. Emamian, E. S.; Hall, D.; Birnbaum, M. J.; Karayiorgou, M.; Gogos, J. A. Convergent evidence for impaired AKT1-GSK3β signalling in schizophrenia. Nat. Genet., 2004, 36, 131-137.
170. Ukai, W.; Ozawa, H.; Tateno, M.; Hashimoto, E.; Saito, T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J. Neural. Transm., 2004, 111, 667-681.
171. Dai, Y.; Wei, Z.; Sephton, C. F.; Zhang, D.; Anderson, D. H.; Mousseau, D. D. Haloperidol induces the nuclear translocation of phosphatidylinositol 3'-kinase to disrupt Akt phosphorylation in PC12 cells. J. Psychiatry Neurosci., 2007, 32, 323-330.
172. Lu, D.; Carson, D. A. Spiperone enhances intracellular calcium level and inhibits the Wnt signalling pathway. BMC Pharmacol., 2009, 9, 13.
173. Beaulieu, J. M. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J. Psychiatry Neurosci., 2011, 36, 4, 110011. doi: 10. 1503/jpn. 110011. [Epub ahead of print].
174. Brennand, K. J.; Simone, A.; Jou, J.; Gelboin-Burkhart, C.; Tran, N.; Sangar, S.; Li, Y.; Mu, Y.; Chen, G.; Yu, D.; McCarthy, S.; Sebat, J.; Gage, F. H. Modelling schizophrenia using human induced pluripotent stem cells. Nature, 2011, 473, 221-225. Erratum: Nature doi:10. 1038/nature10603.
175. Li, X.; Jope, R. S. Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology, 2010, 35, 2143-2154.
176. Malberg, J. E.; Eisch, A. J.; Nestler, E. J.; Duman, R. S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci., 2000, 20, 9104-9110.
177. Pinnock, S. B.; Blake, A. M.; Platt, N. J.; Herbert, J. The roles of BPNF, pCREB and Wnt3a in the latent period preceding activation of progenitor cell mitosis in the adult dentate gyrus by fluoxetine. PLoS One, 2010, 5, e13652.
178. Pilar-Cuéllar, F.; Vidal, R.; Pazos, A. Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects. Br. J. Pharmacol., 2012, 165, 1046-1057.
179. Mostany, R.; Valdizán, E. M.; Pazos, A. A role for nuclear β-catenin in SNRI antidepressant-induced hippocampal cell proliferation. Neuropharmacology, 2008, 55, 18-26.
180. 473-phosphorylation of Akt-1 in PC12 cells. Life Sci., 2010, 86, 309-314.
181. Bhuiyan, M. S.; Tagashira, H.; Fukunaga, K. Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signalling in the thoracic aorta of ovariectomized rats with abdominal aortic banding. Eur. J. Pharmacol., 2011, 650, 621-628.
182. Reddy, K. K.; Lefkove, B.; Chen, L. B.; Govindarajan, B.; Carracedo, A.; Velasco, G.; Carrillo, C. O.; Bhandarkar, S. S.; Owens, M. J.; Mechta-Grigoriou, F.; Arbiser, J. L. The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Pigment Cell Melanoma Res., 2008, 21, 451-456.
183. Basta-Kaim, A.; Budziszewska, B.; Jaworska-Feil, L.; Tetich, M.; Kubera, M.; Leśkiewicz, M.; Lasoń, W. Inhibitory effect of imipramine on the human corticotropin-releasing-hormone gene promoter activity operates through a PI3-K/AKT mediated pathway. Neuropharmacology, 2005, 49, 156-164.